Articles

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

Hôpital St Louis, Assistance Publique-Hôpitaux de Paris and Paris 7 University, Paris, France
Institut Paoli-Calmettes, Marseille, France
Service d’Hématologie, Rouen, France
Hématologie, CHU de Toulouse, France
Service d’Hématologie, Clermont-Ferrand, France
Hôpital Saint Louis, Paris, France
Service d’Hématologie Clinique et de Thérapie Cellulaire, CHU de Bordeaux Hôpital du Haut-Lévêque, Pessac, France
Service d’Hématologie, Angers, France
Service d’Hématologie, Lyon, France
Service d’Hématologie, Lens, France
Hôpital Henri Mondor, Créteil, France
Hôpital Saint Louis, Paris, France
Institut Paoli-Calmettes, Marseille, France
Hôpital St Louis, Assistance Publique-Hôpitaux de Paris and Paris 7 University, Paris, France
Hopital Avicenne and Paris 13 University, France
SBIM, Hôpital Saint Louis, Paris, France
SBIM, Hôpital Saint Louis, Paris, France
Hôpital St Louis, Assistance Publique-Hôpitaux de Paris and Paris 7 University, Paris, France
Vol. 102 No. 4 (2017): April, 2017 https://doi.org/10.3324/haematol.2016.151894